Predicting the risk of mortality and rehospitalization in heart failure patients: a retrospective cohort study by machine learning approach
M Ketabi, A Andishgar, Z Fereidouni… - Clinical …, 2024 - Wiley Online Library
Background Heart failure (HF) is a global problem, affecting more than 26 million people
worldwide. This study evaluated the performance of 10 machine learning (ML) algorithms …
worldwide. This study evaluated the performance of 10 machine learning (ML) algorithms …
[HTML][HTML] Design and methodology of heart failure registry: results of the Persian registry of cardiovascular disease
M Givi, K Heshmat-Ghahdarijani… - Arya …, 2019 - ncbi.nlm.nih.gov
BACKGROUND Heart failure (HF) resulted from ultimate pathway of many cardiovascular
diseases (CVDs) or as a separate entity poses a considerable increasing prevalence and …
diseases (CVDs) or as a separate entity poses a considerable increasing prevalence and …
Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran
R Ravangard, FS Jalali, M Hajahmadi… - Health Economics Review, 2023 - Springer
Background Today, heart failure is one of the leading causes of death and disability in most
developed and developing countries. By 2030, more than 23.3 million people are projected …
developed and developing countries. By 2030, more than 23.3 million people are projected …
Relation between hemoconcentration status and readmission plus mortality rate among Iranian individuals with decompensated heart failure
AY Farsani, M Vakhshoori, A Mansouri… - … Journal of Preventive …, 2020 - journals.lww.com
Background: Hemoconcentration (HC) has been suggested to be a useful biomarker for
determination of optimum diuretic therapy in acute heart failure (HF), but role of this factor in …
determination of optimum diuretic therapy in acute heart failure (HF), but role of this factor in …
Rationale and design of the Persian cardiovascular disease registry (PCVDR): Scale-up of Persian registry of CardioVascular DiseasE (PROVE)
A Khosravi, A Mansouri, F Shahsanayi… - Current Problems in …, 2021 - Elsevier
We aimed to present the methodology of a national registry entitled “Persian CardioVascular
Disease Registry (PCVDR).” Persian Registry Of cardioVascular diseasE (PROVE) was a …
Disease Registry (PCVDR).” Persian Registry Of cardioVascular diseasE (PROVE) was a …
[HTML][HTML] Association of digoxin with mortality and rehospitalization in heart failure patients treated with beta-blockers: Results from the Persian Heart Failure Patient …
M Yazdi, D Shafie, M Givi, M Garakyaraghi… - ARYA …, 2022 - ncbi.nlm.nih.gov
BACKGROUND Numerous clinical trials have reported conflicting results regarding the
benefit of digoxin in treating heart failure (HF) patients. This study was conducted with the …
benefit of digoxin in treating heart failure (HF) patients. This study was conducted with the …
[PDF][PDF] Dấu ấn sinh học mới MR-proANP trong tiên lượng tử vong nội viện suy tim cấp
HV Hồng, TN Văn, TN Chí, NLP Vi… - Tạp Chí Khoa Học …, 2022 - tapchikhoahochongbang.vn
Tóm tắt Đặt vấn đề: Suy tim cấp là bệnh cảnh cấp tính nặng, có tiên lượng tử vong cao. MR-
proANP là dấu ấn sinh học mới, có thể dự báo kết cục của bệnh nhân trong giai đoạn nằm …
proANP là dấu ấn sinh học mới, có thể dự báo kết cục của bệnh nhân trong giai đoạn nằm …